Zydus Cadila's 3-dose Covid-19 vaccine for kids may take more time for approval | Latest News India - Hindustan Times
close_game
close_game

Zydus Cadila's 3-dose Covid-19 vaccine for kids may take more time for approval

Jul 12, 2021 10:39 AM IST

Emergency use approval for ZyCoV-D is likely to take a few more days, said sources.

A vaccine against the coronavirus disease (Covid-19) for children that is being developed by Gujarat-based pharmaceutical company Zydus Cadila may not be available soon as emergency approval from the country’s top drug regulator is likely to take a few more days.

The company has sought emergency use approval of ZyCoV-D, its DNA vaccine against Covid-19 for those aged 12 years and above, from DCGI(Reuters file photo. Representative image)
The company has sought emergency use approval of ZyCoV-D, its DNA vaccine against Covid-19 for those aged 12 years and above, from DCGI(Reuters file photo. Representative image)

On July 1, the company had sought emergency use approval of ZyCoV-D, its DNA vaccine against Covid-19 for those aged 12 years and above, from the Drugs Controller General of India (DCGI). It had presented interim results from Phase-III clinical trials in over 28,000 volunteers. The study is said to have demonstrated safety and efficacy in the interim data.

Hindustan Times - your fastest source for breaking news! Read now.

The data has shown that ZyCoV-D is safe for children in the age group of 12 to 18 years, said the company, which is planning to manufacture 100-120 million doses of the vaccine annually.

The study was carried out "during the peak of the second wave of Covid-19 (in India), reaffirming the vaccine's efficacy against the new mutant strains especially the Delta variant," Zydus said in a statement.

The second indigenous jab after Bharat Biotech's Covaxin, ZyCoV-D is a three-dose vaccine. According to Zydus Cadila, the three doses of ZyCoV-D are to be administered on day 0, day 28, and day 56. The company is also said to be working on a two-dose vaccine.

The DCGI had granted Cadila Healthcare Limited permission to conduct human trials for ZyCoV-D back in July last year, when the company had said its vaccine will hit the markets by June 2021.

Once Zydus receives approval, ZyCoV-D would become the fifth anti-Covid vaccine authorised for use in India, after AstraZeneca and Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Sputnik V that is being developed by Russia's Gamaleya Institute and Moderna.

Unveiling 'Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch Now!

Get Current Updates on India News, Gyanvapi Case, Farmers Protest Live along with Latest News and Top Headlines from India and around the world
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, February 27, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On